«Ф.И.Белялов АРИТМИИ СЕРДЦА Монография Издание шестое, переработанное и дополненное Иркутск, 2014 04.07.2014 УДК 616.12–008.1 ББК 57.33 Б43 Рецензент доктор медицинских наук, зав. кафедрой терапии и кардиологии ГБОУ ДПО ...»

249. Gallagher M.M., Guo X.H., Poloniecki J.D. et al. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol. 2001;38(5):1498–504.

250. Gallagher M.M., Hennessy B.J., Edvardsson N. et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002;40:926–33.

251. Garrat C.J. et al. Value of physical signs in the diagnosis of ventricular tachycardia.

Circulation. 1994;90:3103–7.

252. Gang U.J.O., Jons C., Jorgensen R.Mr, et al. Clinical significance of late high-degree atrioventricular block in patients with left ventricular dysfunction after an acute myocardial infarction. Am Heart J. 2011;162[3]:542–7.

253. Geller J.C., Geller M., Carlson M.D., Waldo A.L. Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation. Am J Card 2001;87:172–7.

254. Gemayel C., Pelliccia A., Thompson P.D. Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2001;38:1773–81.

255. Gerald V.N., Helen V., Jay L. et al. Increasing Prevalence of Atrial Fibrillation and Flutter in the United States. Am J Cardiol. 2009;104[11]:1534–9.

256. Gheorghiade M., Fonarow G.C., van Veldhuisen D.J. et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 2013;34(20):1489– 257. Girolamo E.D., Iorio C.D., Leonzio L. et al. Usefulness of a Tilt Training Program for the Prevention of Refractory Neurocardiogenic Syncope in Adolescents. Circulation.

1999;100:1798–801.

258. Gladstone D.J., Spring M., Dorian P. et al. Prolonged ambulatory cardiac monitoring improves the detection and treatment of atrial fibrillation in patients with cryptogenic stroke. International Stroke Conference 2013; February 7, 2013; Honolulu, HI.

259. Glotzer T.V., Daoud E.G., Wyse D.G. et al. The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk. Circ Arrhythm Electrophysiol. 2009;2(5):474–80.

260. Go A.S., Hylek E.M., Phillips K.A. et al. Prevalence of Diagnosed Atrial Fibrillation in Adults. National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA.

2001;285:2370–5.

261. Goktekin O., Melek M., Gorenek B. et al. Cardiac Troponin T and Cardiac Enzymes After External Transthoracic Cardioversion of Ventricular Arrhythmias in Patients With Coronary Artery Disease. Chest. 2002;122:2050–4.

262. Goldberger J.J., Passman R. Implantable Cardioverter-defibrillator Therapy After Acute Myocardial Infarction: The Results Are Not Shocking. J Am Coll Cardiol.

2009;54(22):2001–5.

263. Goldberger J.J., Johnson N.P., Gidea C. Significance of Asymptomatic Bradycardia for Subsequent Pacemaker Implantation and Mortality in Patients >60 Years of Age.

Am J Cardiol. 2011;108[6]:857–61.

264. Gollob M.H., Green M.S., Tang A.S.L. et al. Identification of a Gene Responsible for Familial Wolff–Parkinson–White Syndrome. N Engl J Med. 2001;344:1823–31.

265. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high–risk and low–risk patients after myocardial infarction. N Engl J Med.

1998;339(8):489–97.

266. Gomes T., Mamdani M.M., Holbrook A.M., et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. Canadian Medical Association Journal. 2012.

267. Goudevenos J.A., Katsouras C.S., Graekas G. et al. Ventricular pre-excitation in the general population: a study on the mode of presentation andclinical course. Heart.

2000; 83:29–34.

268. Gourraud J., Le Scouarnec S., Sacher F. et al. Identification of Large Families in Early Repolarization Syndrome. J Am Coll Cardiol. 2013;61(2):164–72.

269. Goy J.J., Fromer M., Schlaepfer J. et al. Clinical efficacy of radiofrequency current in the treatment of patients with atrioventricular node reentrant tachycardia. J Am Coll Cardiol. 1990;16:418–23.

270. Goyal A., Spertus J.A., Gosch K. et al. Serum Potassium Levels and Mortality in Acute Myocardial Infarction. JAMA 2012;307(2):157–64.

271. Gradman A., Deedwania P., Cody R. et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril–Digoxin Study Group. J Am Coll Cardiol. 1989;14:564–70.

272. Granada J., Uribe W., Chyou P.H. et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36(7):2242–6.

273. Granger C.B., Alexander J.H., McMurray J.J.V. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

274. Granger C.B., Armaganijan L.V. Newer Oral Anticoagulants Should Be Used as FirstLine Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism. Circulation. 2012;125(1):159–64.

275. Green M., Heddle B., Dassen W. et al. Value of QRS alteration in determining the site of origin of narrow QRS supraventricular tachycardia. Circulation. 1983;68:368– 276. Greenspon A.J., Patel J.D., Lau E. et al. 16-Year Trends in the Infection Burden for Pacemakers and Implantable Cardioverter-Defibrillators in the United States: 1993 to 2008. J Am Coll Cardiol. 2011;58(10):1001–6.

277. Greenspon A.J., Prutkin J.M., Sohail M.R. et al. Timing of the Most Recent Device Procedure Influences the Clinical Outcome of Lead-Associated Endocarditis. J Am Coll Cardiol. 2012;59(7):681–7.

278. Greenspon A.J., Patel J.D., Lau E. et al. Trends in Permanent Pacemaker Implantation in the United States From 1993 to 2009: Increasing Complexity of Patients and Procedures. J Am Coll Cardiol. 2012;60(16):1540-–5.

279. Groenveld H.F., Tijssen J.P., Crijns H.M. et al. Rate Control Efficacy in Permanent Atrial Fibrillation: Successful and Failed Strict Rate Control Against a Background of Lenient Rate Control: Data From RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol. 2013;61(7):741–8.

280. Gronefeld G.C., Lilienthal J., Kuck K.-H., Hohnloser S.H. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Eur Heart J.

2003;24:1430–6.

281. Giugliano R.P., Ruff C.T., Braunwald E. et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2013.

282. Gulizia M., Mangiameli S., Orazi S. et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment. Am Heart J. 2008;155:100– 283. Gullov A.L., Koefoed B.G., Petersen P. et al. Fixed Minidose Warfarin and Aspirin Alone and in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation. Arch Intern Med. 1998;158:1513–21.

284. Guntheroth W., Chun L., Patton K.K. et al. Wenckebach Periodicity at Rest That Normalizes With Tachycardia in a Family With a NKX2.5 Mutation. The American journal of cardiology. 2012;110[11]:1646–50.

285. Guyatt G.H., Akl E.A., Crowther M. et al. Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest.

2012;141(2 suppl):7S-47S.

286. Haissaguerre M., Jais P., Shah D.C. et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation.

2000;101:1409–17.

287. Halkin A., Steinvil A., Rosso. et al. Preventing sudden death of athletes with electrographic screening. J Am Coll Cardiol. 2012; 60: 2271–6.

288. Hammill S.C., Kremers M.S., Kadish A.H. et al. Review of the ICD registry's third year, expansion to include lead data and pediatric ICD procedures, and role for measuring performance. Heart Rhythm. 2009;6(9):1397–401.

289. Hart R.G., Pearce L.A., Rothbart R.M. et al. Stroke with intermittent atrial fibrillation:

incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35:183–7.

290. Haverkamp W., Breithardt G., Camm A.J.,et al. The potential for QT prolongation and proarrhythmia by non–antiarrhythmic drugs: clinical and regulatory implications.

Eur Heart J. 2000;21.

291. Healey J.S., Toff W.D., Lamas G.A. et al. Cardiovascular Outcomes With Atrial– Based Pacing Compared With Ventricular Pacing: Meta-Analysis of Randomized Trials, Using Individual Patient Data. Circulation. 2006;114:11–7.

292. Healey J.S., Hallstrom A.P., Kuck K.H. et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J. 2007;28:1746–9.

293. Healey J.S., Connolly S.J., Gold M.R. et al. Subclinical Atrial Fibrillation and the Risk of Stroke. N Engl J Med. 2012;366(2):120–9.

294. Heart Rate and Rhytm: Molecular Basis, Pharmacological Modulation and Clinical Implications. Ed.: O.N.Tripathi et al. 2011. 678 p.

295. Heeringa J., Hoogendoorn E.H., van der Deure W.M. et al. High-Normal Thyroid Function and Risk of Atrial Fibrillation: The Rotterdam Study. Arch Intern Med.

2008;168(20):2219–24.

296. Heneghan C., Ward A., Perera R. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. The Lancet. 2012;379:322–34.

297. Hernandez-Madrid A., Svendsen J.H., Lip G.Y.H. et al. Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey. Europace. 2013;15(6):915–8.

298. Hesse B., Diaz L.A., Snader C.E. et al. Complete bundle branch block as an independent predictor of all-cause mortality: report of 7073 patients referred for nuclear exercise testing. Am J Med. 2001;110:253–9.

299. Hess C.N., Broderick S., Piccini J.P. et al. Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. American heart journal.

2012;164[4]:607–15.

300. Hylek E.M., Evans-Molina C., Shea C. et al. Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation.

Circulation. 2007;115:2689–96.

301. Hindman M.C., Last J.H., Rosen K.M. Wolff-Parkinson-White syndrome observed by portable monitoring. Ann Intern Med. 1973;79:654–63.

302. Hindricks G., Pokushalov E., Urban L. et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: Results of the XPECT trial. Circ Arrhythm Electrophysiol. 2010;3(2):141–7.

303. Hinkle L.E. The indeterminate representation of disorders of conduction and disrythmias on the surface ECG. Circulation. 1981;64:232–4.

304. Hito I., Naoy O., Sane I. et al. The Incidence of Asymptomatic Cerebral Microthromboembolism after Atrial Fibrillation Ablation: Comparison of Warfarin and Dabigatran.

Pacing and Clinical Electrophysiology 2013;36(11):1328–35.

305. Hjortshj S., Riahi S., Nielsen J.C. et al. Does atrial pacing lead to atrial fibrillation in patients with sick sinus syndrome? Insights from the DANPACE trial. Europace.

2014;16(2):241–5.

306. Hnatkova K., Waktare J.E.P., Murgatroyd F.D. et al. Analysis of the Cardiac Rhythm Preceding Episodes of Paroxysmal Atrial Fibrillation. Am Heart J. 1998;135:1010–9.

307. Hof I., Arbab-Zadeh A., Scherr D. et al. Correlation of left atrial diameter by echocardiography and left atrial volume by computed tomography. J Cardiovasc Electrophysiol. 2009;20(2):159–63.

308. Hofman N., Wilde A.A.M., Kaab S. et al. Diagnostic criteria for congenital long QT syndrome in the era of molecular genetics: do we need a scoring system? Eur Heart J.

2007;28(5):575–80.

309. Hofsten D.E., Wachtell K., Lund B. et al. Prevalence and prognostic implications of non–sustained ventricular tachycardia in ST–segment elevation myocardial infarction after revascularization with either fibrinolysis or primary angioplasty. Eur Heart J.

2007;28:407–14.

310. Hohnloser S.H., Klingenheben T., Zabel M.,et al. Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era. J Am Coll Cardiol. 1999;33:1895–902.

311. Hohnloser S.H., Pajitnev D., Pogue J. et al. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An ACTIVE W Substudy. J Am Coll Cardiol. 2007;50:2156–61.

312. Holmes D.R., Reddy V.Y., Turi Z.G. et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non–inferiority trial. Lancet. 2009;374:534–42.

313. Hoyt H., Bhonsale A., Chilukuri K. et al. Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. Heart Rhythm 2011;8:1869–74.

314. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace. 2013;15(10):1389– 315. Hu J., Ma J., Yang Q. et al. The characteristics of verapamil-sensitive idiopathic left ventricular tachycardia combined with a left accessory pathway and the effect of radiofrequency catheter ablation. Europace. 2012;14(5):703–8.

316. Hu D., Barajas-Martnez H., Pfeiffer R. et al. Mutations in SCN10A Are Responsible for a Large Fraction of Cases of Brugada Syndrome. J Am Coll Cardiol. 2014;64(1):66– 317. Huang S.K., Ezri M.D., Hauser R.G., Denes P. Carotid sinus hypersensitivity in patients with unexplained syncope: clinical, electrophysiologic, and long-term follow-up observations. Am Heart J. 1988;116:989–96.

318. Huisman M.V., Lip G.Y., Diener H.C. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thromb Haemost. 2012;107(5):838–47.

319. Hussein A.A., Abutaleb A., Jeudy J. et al. Safety of Computed Tomography in Patients With Cardiac Rhythm Management Devices: Assessment of the U.S. Food and Drug Administration Advisory in Clinical Practice. J Am Coll Cardiol.

2014;63(17):1769–75.

320. Hylek E.M., Evans–Molina C., Shea C. et al. Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation.

Circulation. 2007;115:2689–96.

321. Inada K., Yamane T., Tokutake K-I. et al. The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses: outcome during a 5-year follow-up. Europace. 2014;16(2):208–13.

322. Institute for Clinical Systems Improvement (ICSI). Atrial fibrillation. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2008 Oct. 62 p.

323. Insulander P., Bastani H., Braunschweig F. et al. Cryoablation of substrates adjacent to the atrioventricular node: acute and long-term safety of 1303 ablation procedures.

Europace. 2014;16(2):271–6.

324. Ionescu-Ittu R., Abrahamowicz M., Jackevicius C.A. et al. Comparative Effectiveness of Rhythm Control vs Rate Control Drug Treatment Effect on Mortality in Patients With Atrial Fibrillation. Arch Intern Med. 2012;172(13):997–1004.

325. Issa Z., Miller J.M., Zipes D.P. Clinical arrhythmology and electrophysiology: a companion to Braunwald’s heart disease. 2009. 502 p.

326. Jabre P., Roger V.L., Murad M.H. et al. Mortality Associated With Atrial Fibrillation in Patients With Myocardial Infarction: A Systematic Review and Meta-analysis. Circulation. 2011;123(15):1587–93.

327. Jais P., Cauchemez B., MacLe L. et al. Atrial fibrillation ablation vs antiarrhythmic drugs: A multicenter randomized trial. Heart Rhythm. 2006;3(Suppl):S1–S460.

328. Jarett D.B., Ronald J.P., Linda V.H. et al. Dietary Fish Intake and Incident Atrial Fibrillation (from the Women's Health Initiative). Am J Cardiol. 2010;105[6]:844–8.

329. Joglar J.A., Hamdan M.H., Ramaswamy K. et al. Initial energy for elective external cardioversion of persistent atrial fibrillation. Am J Card. 2000;86:348–50.

330. Johnson J.N., Ackerman M.J. QTc: how long is too long? Br J Sports Med.

2009;43(9):657–62.

331. Josephson M.E., Zimetbaum P.J., Buxton A.E., Marchlinski F.E. The Tachyarrhythmias. In: Harrison's Principles of internal medicine. New York-Toronto 2000.

332. Josephson M.E. New Approaches to the Management of Atrial Fibrillation. The Role of the Atrial Defibrillator. Circulation. 1998; 98:1594–6.

333. Julian D.G., Camm A.J., Frangin G. et al. Randomised trial of effect of amiodarone on mortality in patients with left–ventricular dysfunction after recent MI: EMIAT. Lancet.

1997;349:667–74.

334. Jung F., DiMarco J.P. Treatment Strategies for Atrial Fibrillation. Am J Med.

1998:104:272–86.

335. Kalbfleisch S.J., el Atassi R., Calkins H. et al. Differentiation of paroxysmal narrow QRS complex tachycardias using the 12-lead electrocardiogram. J Am Coll Cardiol. 1993;21:85–9.

336. Kamberi L., Citaku H., Hoxha-Kamberi T. Supraventricular tachycardia in pregnancy.

Med Arh. 2010;64(5):305–6.

337. Kannel W.B., Doyle J.T., McNamara P.M. et al. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation. 1975;51(4):606– 338. Kannel W.B., Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol. 1985; 5:141B–9B.

339. Kapoor W.N. Evaluation and management of the patient with syncope. JAMA. 1992;

268: 2553–60.

340. Kargul W., Wilczek J.,Kowalik J.,et al. Simultaneous Using Of ECG And Blood Pressure Holter Registration In Patients With Pacemaker Syndrome. Heartweb. 1996;2:1.

341. Katritsis D., Camm A.J. AAI pacing mode: when is it indicated and how should it be achieved? Clin Cardiol. 1993;16:339–43.

342. Katritsis D.G., Josephson M.T. Sudden Cardiac Death and Implantable Cardioverter Defibrillators. Europace. 2012;14(6):787–94.

343. Katritsis D.G., Toumpoulis I.K., Giazitzoglou E. et al. Latent arterial hypertension in apparently lone atrial fibrillation. J Interv Card Electrophysiol. 2005;13(3):203–7.

344. Katritsis D.G., Pokushalov E., Romanov A. et al. Autonomic Denervation Added to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial.

J Am Coll Cardiol. 2013;62(24):2318–25.

345. Kennedy H.L., Whitlock J.A., Sprague M.K. et al. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med.

1985;312(4):193–7.

346. Khan I.A. Single oral loading dose of propafenone for pharmacological cardioversion of recent–onset atrial fibrillation. J Am Coll Cardiol. 2001;37:542–7.

347. Khan I.A., Mehta J.H., Gowda R.M. Amiodarone for pharmacological cardioversion of recent–onset atrial fibrillation. Int J Cardiol. 2003; 89:239–48.

348. Khan A.M., Lubitz S.A., Sullivan L.M. et al. Low Serum Magnesium and the Development of Atrial Fibrillation in the Community: The Framingham Heart Study. Circulation. 2013;127(1):33–8.

349. Kim J.S., She F., Jongnarangsin K. et al. Dabigatran vs Warfarin for Radiofrequency Catheter Ablation of Atrial Fibrillation. Heart Rhythm. 2013;10(4):483–9.

350. King D.E., Dickerson L.M., Sack J.L. Acute Management of Atrial Fibrillation:

Part II. Prevention of Thromboembolic Complications. Am Fam Physician.

2002;66:261–72.

351. Kirchhof P., Eckardt L., Loh P. et al. Anterior-posterior versus anterior–lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet.

2002; 360:1275–9.

352. Kirchhof P., Andresen D., Bosch R. et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012 Jun 15.

353. Kirchhof P., Lip G.Y., Van Gelder I.C. et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Europace.

2012;14(1):8–27.   354. Kirchhof P., Breithardt G., Aliot E. et al. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2013;15(11):1540–56.

355. Kirkfeldt R.E., Andersen H.R., Nielsen.JC. System upgrade and its complications in patients with a single lead atrial pacemaker: data from the DANPACE trial. Europace 2013;15(8):1166-73.

356. Kirkland J.L., Lye M., Faragher E.B. et al. A longitudinal study of the prognostic significance of ventricular ectopic beats in the elderly. Gerontology. 1983; 29:199–201.

357. Kiviniemi T., Puurunen M., Schlitt A. et al. Performance of Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. The American journal of cardiology. 2014;113:1995–2001.

358. Kjeldsen S.E., Aksnes T.A., Schmieder R.E. European Society of Hypertension Scientific Newsletter:Hypertension and Atrial Fibrillation with Emphasis on Prevention.

2011.

359. Klein A.L., Grimm R.A., Black I.W. et al. Cardioversion Guided by Transesophageal Echocardiography: The ACUTE Pilot Study. Ann Intern Med. 1997;126:200–9.

360. Klein A.L., Grimm R.A., Murray R.D. et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411– 361. Knight B.P., Goyal R., Pelosi F. et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol. 1999;33:1964–70.

362. Knight B.P., Pelosi F., Michaud G.F. et al. Physician interpretation of electrocardiographic artifact that mimics ventricular tachycardia. Am J Med. 2001;110:335–8.

363. Koepfli P., Wyss C.A., Gaemperli O. et al. Left bundle branch block causes relative but not absolute septal underperfusion during exercise. Eur Heart J.

2009;30(24):2993–9.

364. Kolb C., Nurnberger S., Ndrepepa G. et al. Modes of initiation of paroxysmal atrial fibrillation from analysis of spontaneously occurring episodes using a 12-lead Holter monitoring system. Am J Card. 2001;88:853–7.

365. Kopecky S.L., Gersh B.J., McGoon M.D. et al. The natural history of lone atrial fibrillation: a population–based study over three decades. N Engl J Med. 1987;317:669– 366. Kovoor P., Eipper V., Byth K. et al. Comparison of sotalol with amiodarone for longterm treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. Eur Heart J. 1999;20:364–374.

367. Kou W.H., Calkins H., Lewis R.R. et al. Incidence of loss of consciousness during automatic implantable cardioverter-defibrillator shocks. Ann Intern Med.

1991;115:942–5.

368. Kowey P.R., Marinchak R.A., Rials S.J., Filart R.A. Acute Treatment of Atrial Fibrillation. Am J Card. 1998;81:5A:16C–22C.

369. Kowey P.R., Reiffel J.A., Ellenbogen K.A. et al. Efficacy and safety of prescription omega–3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation. A randomized controlled trial. JAMA. 2010;304(21):2363–72.

370. Koyama T., Tada H., Sekiguchi Y. et al. Prevention of Atrial Fibrillation Recurrence With Corticosteroids After Radiofrequency Catheter Ablation: A Randomized Controlled Trial. J Am Coll Cardiol. 2010;56(18):1463–72.

371. Krahn A.D., Klein G.J., Yee R. The High Cost of Syncope: Cost Implications of a New Insertable Loop Recorder in the Investigation of Recurrent Syncope. Am Heart J. 1999;

137:870–7.

372. Krittayaphong R., Bhuripanyo K., Punlee K., et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J. 2002;144(6):e10.

373. Krahn A.D., Klein G.J., Yee R. A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff–Parkinson–White syndrome. PACE. 2001;24(8 Pt 1):1258–60.

374. Krahn A.D., Klein G.J., Fitzpatrick A. et al. Predicting the outcome of patients with unexplained syncope undergoing prolonged monitoring. Pacing Clin Electrophysiol.

2002;25(1):37–41.

375. Krahn A.D., Healey J.S., Chauhan V. et al. Systematic Assessment of Patients With Unexplained Cardiac Arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER). Circulation. 2009;120(4):278–85.

376. Krahn A.D., Obeyesekere M.N. Inheritance of Early Repolarization and Familial Malignant Forms. J Am Coll Cardiol. 2013;61(2):173–5.

377. Kralev S., Schneider K., Lang S. et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One. 2011;6(9):e24964.

378. Kroenke K., Arrington M.E., Mangelsdorff A.D. The prevalence of symptoms in medical outpatients and the adequacy of therapy. Arch Intern Med. 1990;150:1685–90.

379. Kuck K.H., Schaumann A., Eckardt L. et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. The Lancet. 2010;375:31–40.

380. Kuhlkamp V., Mewis C., Mermi J. et al. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l–sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol. 1999;33:46–52.

381. Krummen D.E., Gregory K.F., Sanjiv M.N. Diagnostic Accuracy of Irregularly Irregular RR Intervals in Separating Atrial Fibrillation from Atrial Flutter. Am J Cardiol.

2006;98[2]:209–14.

382. Kubzansky L.D., Park N., Peterson C. et al. Healthy Psychological Functioning and Incident Coronary Heart Disease: The Importance of Self-regulation. Arch Gen Psychiatry. 2011;68(4):400–8.

383. Lafuente-Lafuente C., Longas-Tejero M.A., Bergmann J.F., Belmin J.

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.

Cochrane Database of Systematic Reviews 2012, Issue 4.

384. Lai L.-P., Lin J.-L., Lien W.-P. et al. Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: assessment of the electrophysiological effects by biatrial basket electrodes. J Am Coll Cardiol.

2000;35:1434–41.

385. Laish-Farkash A., Khalameizer V., Katz A. Atrial Fibrillation in the Elderly. J Cardiovasc Electrophysiol. 2013;24(7):739–41.

386. Lakkireddy D., Reddy Y.M., Di Biase L. et al. Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation. J Am Coll Cardiol. 2012;59(13):1168–74.

387. Lakkireddy D., Reddy Y., Di Biase L., et al. Feasibility and Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation. J Am Coll Cardiol. 2014;63(10):982–8.

388. Lam J., Gomes T., Juurlink D.N. et al. Hospitalization for Hemorrhage Among Warfarin Recipients Prescribed Amiodarone. The American journal of cardiology.

2013;112[3]:420–3.

389. Lamas G.A., Lee K.L., Sweeney M.O. et al. Ventricular Pacing or Dual-Chamber Pacing for Sinus-Node Dysfunction. N Engl J Med. 2002;346:1854–62.

390. Lamb T.S., Thakrar A., Ghosh M. et al. Comparison of two oscillometric blood pressure monitors in subjects with atrial fibrillation. Clinical & Investigative Medicine.

2010;33.

391. Lambiase P.D., Barr C., Theuns D.A.M.J. et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. European Heart Journal. 2014;35:1657–65.

392. Lande G., Kyndt F., Baro I. et al. Dynamic analysis of the QT interval in long QT syndrome patients with a normal phenotype. Eur Heart J. 2001;22(5):363–9.

393. Landers M.D., Reiter M.J. General Principles of Antiarrhythmic Therapy for Ventricular Tachyarrhythmias. Am J Card. 1997;80:8A:31G–44G.

394. Larsen G.C., Stupey M.R., Walance C.G. et al. Recurrent cardiac events in survivors of ventricular fibrillation or tachycardia: implications for driving restrictions. JAMA.

1994;271:1335–9.

395. Larsen B.T., Maleszewski J.J., Edwards W.D. et al. Atrial Giant Cell Myocarditis: A Distinctive Clinicopathologic Entity. Circulation. 2013;127(1):39–47.

396. Laurens P., Gavelle P., Farge C. et al. Isotope cardiac stimulation and pregnancy.

Apropos of 25 cases. Arch Mal Coeur Vaiss. 1983;76(6):733–8.

397. Lechat P., Packer M., Chalon S. et al. Clinical Effects of B–Adrenergic Blockade in Chronic Heart Failure. A Meta-analysis of Double-Blind, Placebo-Controlled, Randomized Trials. Circulation. 1998;98:1184–91.

398. Lee S.H. et al. Comparisons of Quality of Life and Cardiac Performance After Complete Atrioventricular Junction Ablation and Atrioventricular Junction Modification in Patients With Medically Refractory Atrial Fibrillation. J Am Coll Cardiol. 1998;31:637–44.

399. Lee S.J., Shin D.H., Hwang H.J. et al. Bleeding Risk and Major Adverse Events in Patients With Previous Ulcer on Oral Anticoagulation Therapy. The American journal of cardiology. 2012;110[3]:373–7.

400. LeLorier P., Krahn A.D., Klein G.J. et al. Comparison of patients with syncope with left ventricular dysfunction and negative electrophysiologic testing to cardiac arrest survivors and patients with syncope and preserved left ventricular function and impact of and impact of an implantable defibrillator. Am J Card. 2002;90:77–9.

401. Lellouche N., Sacher F., Jorrot P. et al. Sudden cardiac arrest: ECG repolarization after resuscitation. J Cardiovasc Electrophysiol. 2011;22(2):131–6.

402. Levy S., Ricard Ph., Pak Lau C. et al. Multicenter low energy transvenous atrial defibrillation (XAD) trial. Results in different subjects of atrial fibrillation. J Am Coll Cardiol.

1997;29:750–5.

403. Leong-Sit P., Roux J.F., Zado E. et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ Arrhythm Electrophysiol. 2011;4(1):11– 404. Levy S., Rodriguez L.M., Camm J. et al. Number, duration and frequency of nontreated atrial fibrillation episodes observed during the metrix automatic implantable defibrillator trial. PACE. 1998;21:811.

405. Levy S., Maarek M., Coumel P. et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA Study, The College of French Cardiologists. Circulation. 1999;99:3028–35.

406. Levy S., Sbragia P. ECG repolarization syndrome abnormalities (J wave syndromes) and idiopathic ventricular fibrillation: diagnostic and management. J Interv Card Electrophysiol. 2011;32(3):181–6.

407. Liberthson R.R., Nagel E.L., Hirschman J C.,Nussenfeld S.R. Prehospital ventricular fibrillation: Prognosis and follow-up course. N Engl J Med. 1974;291:317.

408. Lin H.J., Wolf P.A., Benjamin E.J. et al. Newly diagnosed atrial fibrillation and acute stroke. The Framingham Study. Stroke. 1995; 26:1527–30.

409. Link M.S., Hellkamp A.S., Estes M. et al. High incidence of pacemaker syndrome in patients with sinus node dysfunction treated with ventricular-based pacing in the Mode Selection Trial (MOST). JACC. 2004;43:2066–71.

410. Link M.S., Luttmann-Gibson H., Schwartz J., et al. Acute Exposure to Air Pollution Triggers Atrial Fibrillation. J Am Coll Cardiol. 2013;62(9):816–25.

411. Lip G.Y.H.,Frison L.,Grind M. et al. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28:752–9.

412. Lip G.Y.H., Nieuwlaat R., Pisters R. et al. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor– Based Approach. Chest. 2010;137(2):263–72.

413. Lip G.H., Larsen T., Skjoth F., Rasmussen L. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. 2012;60(8):738–46.

414. Lip G.Y.H., Gitt A.K., Le Heuzey J.-Y. et al. Overtreatment and Undertreatment With Anticoagulation in Relation to Cardioversion of Atrial Fibrillation (the RHYTHM-AF Study). The American journal of cardiology. 2014;113(3):480–4.

415. Linde C.L., Bocray A., Jonsson H. et al. Re-used pacemakers — as safe as new? A retrospective case–control study. Eur Heart J. 1998;19(3): 416. Linzer M., Yang E.H., Estes N.A.M. et al. Diagnosing Syncope. Part 1: Value of History, Physical Examination and Electrocardiography. Ann Intern Med. 1997;126:989– 417. Linzer M., Yang E.H., Estes N.A.M. et al. Diagnosing Syncope. Part 2: Unexplained Syncope. Ann Intern Med. 1997;127:76–86.

418. Lip G.Y.H., Zarifis J., Beevers M., Beevers D.G. Ambulatory blood pressure monitoring in atrial fibrillation. Am J Cardiol. 1996;78:350–3.

419. Lip G.Y.H., Zarifis J., Beevers D.G. Blood Pressure Monitoring in Atrial Fibrillation Using Electronic Devices. Arch Int Med. 2001;161:2.

420. Lokshyn S., Mewis C., Kuhlkamp V. Atrial fibrillation in coronary artery disease. Int J Cardiol. 2000;72(2):133–6.

421. Lopes R.D., Siha H., Fu Y. et al. Diagnosing Acute Myocardial Infarction in Patients With Left Bundle Branch Block. Am J Cardiol. 2011;108[6]:782–8.

422. Lubitz S.A., Yin Х., Fontes J.D. et al. Association Between Familial Atrial Fibrillation and Risk of New–Onset Atrial Fibrillation. JAMA. 2010. doi:10.1001/jama.2010.1690.

423. Luk J.H., Walsh B., Yasbin P. Safety and efficacy of prehospital diltiazem. West J Emerg Med. 2013;14(3):296–300.

424. Lund M., French J.K., Johnson R.N. et al. Serum troponins T and I after elective cardioversion. Eur Heart J. 2000;21:245–53.

425. Macchia A., Grancelli H., Varini S. et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD trial. J Am Coll Cardiol. 2013;61(4):463–8.

426. Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42:20–9.

427. Malhotra R., Bilchick K.C., DiMarco J.P. Usefulness of Pharmacologic Conversion of Atrial Fibrillation During Dofetilide Loading Without the Need for Electrical Cardioversion to Predict Durable Response to Therapy. The American journal of cardiology.

2014;113(3):475–9.

428. Malik R., Hodgson H. The relationship between the thyroid gland and the liver. QJM.

2002;95(9):559–69.

429. Management of Cardiac Arrhythmias. Edited by G.-X. Yan, P.R.Kowey. 2011. 485 p.

430. Mandell J., Amico F., Parekh S. et al. Early experience with the cryoablation balloon procedure for the treatment of atrial fibrillation by an experienced radiofrequency catheter ablation center. J Invasive Cardiol. 2013;25(6):288–92.

431. Mandyam M.C., Vedantham V., Scheinman M.M. et al. Alcohol and Vagal Tone as Triggers for Paroxysmal Atrial Fibrillation. The American journal of cardiology.

2012;110[3]:364–8.

432. Manegold JC, Israel CW, Ehrlich JR et al. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems. Eur Heart J.

2007;28:1731–8.

433. Manning W.J., Silverman D.I., Keighley C.S. et al Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short–term anticoagulation: final results of a prospective 4,5-year study. J Am Coll Cardiol.

1995;25:1354–61.

434. Mansourati J., Larlet J.–M., Salaun G. et al. Safety of High Energy Internal Cardioversion for Atrial Fibrillation. PACE. 1997;20:8:1919.

435. Mant J., Hobbs R., Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA). Lancet. 2007; 370:493–503.

436. Marfella R., Sasso F., Siniscalchi M., et al. Brief Episodes of Silent Atrial Fibrillation Predict Clinical Vascular Brain Disease in Type 2 Diabetic Patients. J Am Coll Cardiol.

2013;62(6):525–30.

437. Marine J.E., Shetty V., Chow GV. et al. Prevalence and Prognostic Significance of Exercise-Induced Nonsustained Ventricular Tachycardia in Asymptomatic Volunteers:

BLSA (Baltimore Longitudinal Study of Aging). J Am Coll Cardiol. 2013;62(7):595–600.

438. Maron B.J., Shirani J., Poliac L.C. et al. Sudden death in young competitive athletes:

clinical, demographic, and pathological profiles. JAMA. 1996;276:199–204.

439. Maron B.J., Doerer J.J., Haas T.S. et al. Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006. Circulation.

2009;119(8):1085–92.

440. Marcus F.I. The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Am J Cardiol. 1990;66:366–367.

441. Martino E., Safran M., Aghini–Lomardi F. et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med. 1984;101:28–34.

442. Marquez M.F., Colin L., Guevara M. et al. Common electrocardiographic artifacts mimicking arrhythmias in ambulatory monitoring. Am Heart J. 2002;144(2):187–97.

443. Martin A.B., Perry J.C., Robinson J.L. et al. Calculation of QTc duration and variability in the presence of sinus arrhythmia. Am J Cardiol. 1995;75[14]:950–2.

444. Martinek M., Sigmund E., Lemes C. et al. Asymptomatic cerebral lesions during pulmonary vein isolation under uninterrupted oral anticoagulation. Europace.

2013;15(3):325–31.

445. Martinez–Marcos F.J., Garcia–Garmendia J.L., Ortega–Carpio A. et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Card. 2000;86:950–6.

446. Matchar D.B., Jacobson A., Dolor R. et al. Effect of Home Testing of International Normalized Ratio on Clinical Events. N Engl J Med. 2010;363(17):1608–20.

447. Matsuo K., Akahoshi M., Nakashima E. et al. The prevalence, incidence and prognostic value of the Brugada–type electrocardiogram : A population-based study of four decades. J Am Coll Cardiol. 2001;38:765–70.

448. Mazzanti A., Kanthan A., Monteforte N. et al. Novel Insight Into the Natural History of Short QT Syndrome. J Am Coll Cardiol. 2014;63(13):1300–8.

449. McGorrian C., Constant O., Harper N. et al. Family-based cardiac screening in relatives of victims of sudden arrhythmic death syndrome. Europace. 2013;15(7):1050–8.

450. McKenna W.J., Thiene G., Nava A. et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy: task force of the working group myocardial and pericardial disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J. 1994;71:215–8.

451. Medi C., Kalman J.M., Haqqani H. et al. Tachycardia–Mediated Cardiomyopathy Secondary to Focal Atrial Tachycardia: Long-term Outcome After Catheter Ablation. J Am Coll Cardiol. 2009;53(19):1791–7.

452. Medi C., Evered L., Silbert B., et al. Subtle Post-Procedural Cognitive Dysfunction After Atrial Fibrillation Ablation. J Am Coll Cardiol. 2013;62(6):531–9.

453. Mehra A., Ostrzega E., Widerhorn J. et al. Arrhythmias in pregnancy: Prevalence and effect on fetal and maternal outcome in a large group of asymptomatic women.

Clin Res. 1991;39:79a.

454. Medeiros-Domingo A., Iturralde-Torres P., Ackerman M.J. Clinical and genetic characteristics of long QT syndrome. Rev Esp Cardiol. 2007;60(7):739–52.

455. Mendu M.L., McAvay G., Lampert R. et al. Yield of Diagnostic Tests in Evaluating Syncopal Episodes in Older Patients. Arch Intern Med. 2009;169(14):1299–305.

456. Meinertz T., Hofmann T., Kasper W. et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol. 1984; 53: 902–7.

457. Merlos P., Rumiz E., Ruiz-Granell R. et al. Outcome of patients with syncope beyond the implantable loop recorder. Europace. 2013;15(1):122–6.

458. Mezu U., Adelstein E., Jain S. et al. Effectiveness of Implantable Defibrillators in Octogenarians and Nonagenarians for Primary Prevention of Sudden Cardiac Death. Am J Cardiol. 2011;108:718–22.

459. Michaud G.F., Strickberger S.A. Should an abnormal serum potassium concentration be considered a correctable cause of cardiac arrest? J Am Coll Cardiol.

2001;38(4):1224–5.

460. Middlekau H.R., Stevenson W.G., Stevenson L.W., Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol. 1993; 21:110–6.

461. Miller R. Debate on Therapy for VT With Sustained Ventricular Function. Medscape.

2011.

462. Mittal S., Ayati S., Stein K.M. et al. Transthoracic Cardioversion of Atrial Fibrillation.

Comparison of Rectilinear Biphasic Versus Damped Sine Wave Monophasic Shocks.

Circulation. 2000;101:1282.

463. Mohanty S., Mohanty P., Di Biase L. et al. Results From a Single-Blind, Randomized Study Comparing the Impact of Different Ablation Approaches on Long-Term Procedure Outcome in Coexistent Atrial Fibrillation and Flutter. Circulation.

2013;127(18):1853–60.

464. Monnig G., Kobe J., Loher A. et al. Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: A long-term follow-up. Europace.

2012; 14(3):396–401.

465. Mont L., Elosua R., Brugada J. Endurance Sport Practice as a Risk Factor for Atrial Fibrillation and Atrial Flutter. Europace. 2009;11(1):11–7.

466. Moreyra E., Finkelhor R.S., Cebul R.D. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J. 1995;129:71–5.

467. Morganroth J., Michelson E.L., Horowitz L.N. et al. Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency. Circulation.

1978;58(3 Pt 1):408–14.

468. Morganroth J. Ambulatory electrocardiographic monitoring in the evaluation of new antiarrhythmic drugs. Circulation. 1986;72:suppl 2:92–7.

469. Morichetti A., Astorino G. Epidemiological and clinical findings in 697 syncope events. Minerva Medica. 1998; 89:211–20.

470. Morillo C., Verma A., Kuck K.H. et al. Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Symptomatic Atrial Fibrillation: (RAAFT 2): A randomized trial. Heart Rhythm Society 2012 Scientific Sessions; May 11, 2012.

471. Morita H.,Morita S.T.,Nagase S. et al. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol. 2003;42:1624– 472. Moss A.J. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol. 1993;72: 23B–25B.

473. Moss A.J., Zareba W., Hall W.J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med.

2002;346(12):877–83.

474. Moya A., Garcia–Civera R., Croci F. et al. Diagnosis, management, and outcomes of patients with syncope and bundle branch block. Eur Heart J. 2011;32(12):1535–41.

475. Mugnai G., Chierchia G.-B., de Asmundis C. et al. Comparison of Pulmonary Vein Isolation Using Cryoballoon Versus Conventional Radiofrequency for Paroxysmal Atrial Fibrillation. The American journal of cardiology. 2014;113(9):1509–13.

476. Musat D.L., Adhaduk M., Preminger M.W. et al. Correlation of QT Interval Correction Methods During Atrial Fibrillation and Sinus Rhythm. The American journal of cardiology. 2013;112[9]:1379–83.

477. Murray R.D., Goodman A.S., Lieber E.A. et al. National use of the transesophageal echocardiographic–guided approach to cardioversion for patients in atrial fibrillation.

Am J Card. 2000;85:239–44.

478. Myerburg R.J., Conde C.A., Sung R.J. et al. Clinical, electrophysiologic, and hemodynamic profile of patients resuscitated from prehospital cardiac arrest. Am J Med.

1980;68:568.

479. Nademanee K., Oketani N. The Role of Complex Fractionated Atrial Electrograms in Atrial Fibrillation Ablation: Moving to the Beat of a Different Drum. J Am Coll Cardiol.

2009;53(9):790-1.

480. Nadkarni V.M., Larkin G., Peberdy M. et al. First Documented Rhythm and Clinical Outcome From In-Hospital Cardiac Arrest Among Children and Adults. JAMA.

2006;295(1):50–7.

481. Naehle C.P., Kreuz J., Strach K. et al. Safety, feasibility, and diagnostic value of cardiac magnetic resonance imaging in patients with cardiac pacemakers and implantable cardioverters/defibrillators at 1.5 T. Am Heart J. 2011;161[6]:1096–105.

482. Nagarakanti R., Ezekowitz M.D., Oldgren J. et al. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion.

Circulation. 2011;123(2):131–6.

483. Nagappan R., Arora S., Winter C. Potential Dangers of the Valsalva Maneuver and Adenosine in Paroxysmal Supraventricular Tachycardia — Beware Preexcitation. Critical Care and Resuscitation. 2002; 4:107–11.

484. Nagarakanti R., Ezekowitz M.D., Oldgren J. et al. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion. Circulation. 2011;123(2):131–6.

485. Nakazawa H., Lythall D.A., Noh J. et al. Is there a place for the late cardioversion of atrial fibrillation?. A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J. 2000;21:327–33.

486. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post–thyrotoxic state. Am J Med. 1982;72: 903–6.

487. Narayan S.M., Krummen D.E. et al. Treatment of Atrial Fibrillation by the Ablation of Localized Sources: CONFIRM Trial. J Am Coll Cardiol. 2012;60(7):628–36.

488. Narayan S.M., Baykaner T., Clopton P. et al. Ablation of Rotor and Focal Sources Reduces Late Recurrence of Atrial Fibrillation Compared With Trigger Ablation Alone.

J Am Coll Cardiol. 2014;63(17):1761– 489. Natale A., Pisano E., Beheiry S. et al. Ablation of right and left atrial premature beats following cardioversion in patients with chronic atrial fibrillation refractory to antiarrhythmic drugs. Am J Card. 2000;85:1372–5.

490. Nava S., Morales J.L., Marquez MF, et al. Reuse of Pacemakers: Comparison of Short and Long-term Performance. Circulation. 2013;127(11):1177–83.

491. Nayyar S., Ganesan A.N., Brooks A.G. et al. Venturing into ventricular arrhythmia storm: a systematic review and meta-analysis. Eur Heart J. 2013;34(8):560–71.

492. Nazif T.M., Vazquez J., Honig L.S. et al. Anti-N-methyl-d-aspartate receptor encephalitis: an emerging cause of centrally mediated sinus node dysfunction. Europace.

2012;14(8):1188–94.

493. Nielsen J.C., Thomsen P.E., Hjberg S. et al. A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome. Eur Heart J. 2011;32(6):686–96.

494. Niwano S., Wakisaka Y., Niwano H. et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Br Heart J. 2009;95(15):1230–7.

495. Nishida K., Qi X.Y., Wakili R. et al. Mechanisms of Atrial Tachyarrhythmias Associated With Coronary Artery Occlusion in a Chronic Canine Model. Circulation.

2011;123(2):137–46.

496. Nodari S., Triggiani M., Campia U. et al. n-3 Polyunsaturated Fatty Acids in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion / Clinical Perspective. Circulation. 2011;124(10):1100–6.

497. Nucifora G., Schuijf J.D., Tops L.F. et al. Prevalence of coronary artery disease assessed by multislice computed tomography coronary angiography in patients with paroxysmal or persistent atrial fibrillation. Circ Cardiovasc Imaging. 2009;2(2):100–6.

498. O'Callaghan P.A., Poloniecki A., Sosa-Suarez G. et al. Long-term clinical outcome of patients with prior myocardial infarction after palliative radiofrequency catheter ablation for frequent ventricular tachycardia. Am J Card. 2001;87:975–9.

499. Oakes R.S., Badger T.J., Kholmovski E.G. et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009;119(13):1758–67.

500. Ofman P., Khawaja O., Rahilly-Tierney C.R., et al. Regular physical activity and risk of atrial fibrillation: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2013;6(2):252–6.

501. Ogunyankin K.O., Singh B.N. Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: significance of combining beta blockers and amiodarone. Am J Card. 1999;84:9A:76–82.

502. Oh J.H., Hanusa B.H., Kapoor W.N. Do Symptoms Predict Cardiac Arrhythmias and Mortality in Patients With Syncope? Arch Intern Med. 1999;159:375–80.

503. Ouyang F., Tilz R., Chun J. et al. Long-term Results of Catheter Ablation in Paroxysmal Atrial Fibrillation: Lessons From a 5-year Follow-up. Circulation.

2010;122(23):236–77.

504. O'Kelly B., Browner W.S., Massie B. et al. Ventricular arrhythmias in patients undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group.

JAMA. 1992;268:217–21.

505. Okin P.M., Wachtell K., Devereux R.B. et al. Regression of Electrocardiographic Left Ventricular Hypertrophy and Decreased Incidence of New-Onset Atrial Fibrillation in Patients With Hypertension. JAMA. 2006;296:1242–8.

506. Omran H., Luderitz B. Transesophageal echocardiography during cardioversion of atrial fibrillation. Am J Card. 2001;87:126.

507. O'Neil B., Klein G., Guiraudon G. Results of operative therapy in the permanent form of junctional reciprocating tachycardia. Am J Cardiol. 1989;63:1074–9.

508. O'Neill J.O., Young J.B., Pothier C.E., Lauer M.S. Severe frequent ventricular ectopy after exercise as a predictor of death in patients with heart failure. J Am Coll Cardiol.

2004;44(4):820–6.

509. Oral H., Souza J.J., Michaud G.F. et al. Facilitating Transthoracic Cardioversion of Atrial Fibrillation with Ibutilide Pretreatment. N Engl J Med. 1999;340:1849–54.

510. Oral H., Pappone C., Chugh A. et al. Circumferential Pulmonary-Vein Ablation for Chronic Atrial Fibrillation. N Engl J Med. 2006;354:934–41.

511. Orejarena L.A., Vidaillet H., DeStefano F. et al. Paroxysmal Supraventricular Tachycardia in the General Population. J Am Coll Cardiol. 1998;31:150–7.

512. O'Riordan M. STOP–AF and CABANA: Trials Show Effectiveness of Ablation Over Drugs in AF. 2010. www.medscape.com.

513. Osmonov D., Erdinler I., Ozcan K.S., Altay S. et al. Management of patients with drug–induced atrioventricular block. Pacing Clin Electrophysiol. 2012;35(7):804–10.

514. PACES/HRS Expert Consensus Statement on the Management of the Asymptomatic Young Patient with a Wolff–Parkinson–White (WPW, Ventricular Preexcitation) Electrocardiographic Pattern. Heart Rhythm. 2012; 9 (6): 1006–24.

515. Pacifico A., Hohnloser S.H., Williams J.H. et al. Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol. N Engl J Med. 1999;340:1855–62.

516. Page R.L., Wilkinson W.E., Clair W.K. et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994, 89:224–7.

517. Packer D.L., Prutkin J.M., Hellkamp A.S. et al. Impact of Implantable CardioverterDefibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure. Circulation. 2009;120(22):2170–6.

518. Pantos I., Katritsis G., Zografos T. et al. Temporal Stability of Atrial Electrogram Fractionation in Patients With Paroxysmal Atrial Fibrillation. The American journal of cardiology. 2013;111[6]:863–8.

519. Parmar M.S. Thyrotoxic Atrial Fibrillation. Medscape General Medicine.

2005;7(1):74.

520. Paparella N., Ouyang F., Fuc G. et al. Significance of newly acquired negative T waves after interruption of paroxysmal reentrant supraventricular tachycardia with narrow QRS complex. Am J Card. 2000;85:261–3.

521. Pappone C., Vicedomini G., Manguso F. et al. Risk of Malignant Arrhythmias in Initially Symptomatic Patients With Wolff-Parkinson-White Syndrome. Circulation.

2012;125(5):661–8.

522. Parikh M.G., Aziz Z., Krishnan K. et al. Usefulness of Transesophageal Echocardiography to Confirm Clinical Utility of CHA2DS2-VASc and CHADS2 Scores in Atrial Flutter. Am J Cardiol. 2012;109[4]:550–5.

523. Parikh S.S., Jons C., McNitt S. et al. Predictive capability of left atrial size measured by CT, TEE, and TTE for recurrence of atrial fibrillation following radiofrequency catheter ablation. Pacing Clin Electrophysiol. 2010;33(5):532–40.

524. Parvez B., Vaglio J., Rowan S. et al. Symptomatic Response to Antiarrhythmic Drug Therapy Is Modulated by a Common Single Nucleotide Polymorphism in Atrial Fibrillation. J Am Coll Cardiol. 2012;60(6):539–45.

525. Patel A.M., Westveer D.C., Man K.C. et al. Treatment of underlying atrial fibrillation:

paced rhythm obscures recognition. J Am Coll Cardiol. 2000;36:784–7.

526. Patel R.B., Ng J., Reddy V. et al. Early repolarization associated with ventricular arrhythmias in patients with chronic coronary artery disease. Circ Arrhythm Electrophysiol. 2010;3(5):489–95.

527. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883–91.

528. Patel R.B., Ilkhanoff L., Ng J. et al. Clinical Characteristics and Prevalence of Early Repolarization Associated With Ventricular Arrhythmias Following Acute ST-Elevation Myocardial Infarction. The American journal of cardiology. 2012;110[5]:615–20.

529. Patel P.J., Verdino R.J. Usefulness of QRS Axis Change to Predict Mortality in Patients With Left Bundle Branch Block. The American journal of cardiology.

2013;112[3]:390–4.

530. Patel S.V., Flaker G. Is early cardioversion for atrial fibrillation safe in patients with spontaneous echocardiographic contrast? Clin Cardiol. 2008;31(4):148–52.

531. Patten M., Maas R. Event–recorder monitoring for differentiation of symptomatic and asymptomatic episodes of paroxysmal atrial fibrillation. Circulation. 1999;100:I–286.

532. Pelliccia A., Fagard R., Bjornstad H.H. et al. Recommendations for competitive sports participation in athletes with cardiovascular disease. Eur Heart J.

2005;26:1422–45.

533. Penela D., Van Huls Vans Taxis C., Aguinaga L. et al. Neurohormonal, Structural, and Functional Recovery Pattern After Premature Ventricular Complex Ablation Is Independent of Structural Heart Disease Status in Patients With Depressed Left Ventricular Ejection Fraction: A Prospective Multicenter Study. J Am Coll Cardiol.

2013;62(13):1195–202.

534. Petch M.C., Halinen N.M., Block P. et al. Driving and heart disease. Eur Heart J.

1998;19:1165–77.

535. Peters S., Peters H., Thierfelder L. Risk stratification of sudden cardiac death and malignant ventricular arrhythmias in right ventricular dysplasia-cardiomyopathy. Int J Cardiol. 1999;71:243–50.

536. Petersen P., Hansen J.M. Stroke in thyrotoxicosis with atrial fibrillation. Stroke.

1988;18:15–18.

537. Peterson P.N., Varosy P.D., Heidenreich P.A. et al. Association of Single- vs DualChamber ICDs With Mortality, Readmissions, and Complications Among Patients Receiving an ICD for Primary Prevention. JAMA. 2013;309(19):2025–34.

538. Peterson P.N., Greiner M.A., Qualls L.G., et al. QRS Duration, Bundle-Branch Block Morphology, and Outcomes Among Older Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. JAMA. 2013;310(6):617–26.

539. Peuhkurinen K., Niemel M., Ylitalo A. et al. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol. 2000;85(4):462–5.

540. Phillips B.G., Gandhi A.J., Sanoski C.A. et al. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy. 1997;17(6):1238–45.

541. Piccini J.P., Berger J.S., Brown D.L. Early Sustained Ventricular Arrhythmias Complicating Acute Myocardial Infarction. Am J Med. 2008;121:797–804.

542. Piccini J.P., Stevens S.R., Lokhnygina Y. et al. Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial. J Am Coll Cardiol. 2013;61(19):1998–2006.

543. Piccini J.P., Hammill B.G., Sinner M.F. et al. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. European Heart Journal. 2014;35(4):250–6.

544. Pierre-Louis B., Aronow W.S., Palaniswamy C. et al. Obstructive coronary artery disease in high-risk diabetic patients with and without atrial fibrillation. Coron Artery Dis.

2009;20(2):91–3.

545. Pinski S.L., Sgarbossa E.B., Ching E., Trohman R.G. A Comparison of 50–J Versus 100–J Shocks for Direct–Current Cardioversion of Atrial Flutter. Am Heart J.

1999;137:439–42.

546. Pires L.A., May L.M., Ravi S. et al. Comparison of event rates and survival in patients with unexplained syncope without documented ventricular tachyarrhythmias versus patients with documented sustained ventricular tachyarrhythmias both treated with implantable cardioverter–defibrillators. Am J Card. 2000;85:725–8.

547. Pison L., La Meir M., van Opstal J. et al. Hybrid Thoracoscopic Surgical and Transvenous Catheter Ablation of Atrial Fibrillation. J Am Coll Cardiol. 2012;60(1):54–61.

548. Pisters R., van Oostenbrugge R.J., Knottnerus I.L.H. et al. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace.

2010;12(6):779–84.

549. Plewan A., Lehmann G., Ndrepepa G. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation. Sotalol vs bisoprolol. Eur Heart J.

2001;22:1504–10.

550. Polanczyk C.A., Goldman L., Marcantonio E.R. et al. Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med. 1998;129:279–85.

551. Posada I.S., Barriales V. et al. Alternate-Day Dosing of Aspirin in Atrial Fibrillation.

Am Heart J. 1999;138:137–43.

552. Poutiainen A.–M., Koistinen M.J., Airaksinen K.E.J. et al. Prevalence and natural course of ectopic atrial tachycardia. Eur Heart J. 1999;20:694–700.

553. Pramil C., Fan H., Ian P. et al. Relation of Atrial and/or Ventricular Premature Complexes on a Two–Minute Rhythm Strip to the Risk of Sudden Cardiac Death. Am J Cardiol. 2011;107[2]:151–5.

554. Priori S.G., Schwartz P.J., Napolitano C. et al. Risk stratification In the long–QT syndrome. N Engl J Med. 2003;348:1866–74.

555. Pritchett E.L.C., Wilkinson W.E. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol. 1991;67:976–80.

556. Proclemer A., Dagres N., Marinskis G. et al. Current practice in Europe: how do we manage patients with ventricular tachycardia? European Heart Rhythm Association survey. Europace. 2013;15(2):167–9.

557. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass surgery. N Engl J Med. 1997; 337:1569– 558. Ptaszynski P., Kaczmarek K., Ruta J. et al. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013;15(1):116–21.

559. Oudijk M.A., Ruskamp J.M., Ververs F.F.T. et al. Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. J Am Coll Cardiol.

2003;42:765–70.

560. Radsel P., Knafelj R., Kocjancic S. et al. Angiographic Characteristics of Coronary Disease and Postresuscitation Electrocardiograms in Patients With Aborted Cardiac Arrest Outside a Hospital. Am J Cardiol. 2011;108:634–8.

561. Rahimi K., Emberson J., McGale P. et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ. 2011;342.

562. Ranthe M.V., Winkel B.G., Andersen E.W. et al. Risk of cardiovascular disease in family members of young sudden cardiac death victims. Eur Heart J. 2012.

doi:10.1093/eurheartj/ehs350.

563. Rash A., Downes T., Portner R. et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007;36(2):151–6.

564. Raunso J., Selmer C., Olesen J.B. et al. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation.

Eur Heart J. 2012;33(15):1886–92.

565. Ray W.A., Murray K.T., Hall K. et al. Azithromycin and the Risk of Cardiovascular Death. New England Journal of Medicine. 2012;366(20):1881–90.

566. Reddy V.Y., Doshi S.K., Sievert H. et al. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF Trial. Circulation. 2013;127(6):720–9.

567. Reid J.R., Wheeler S.F. Hyperthyroidism: Diagnosis and Treatment. Am Fam Physician. 2005;72:623–30, 635–6.

568. Reiffel J.A. Selecting an antiarrhythmic agent for atrial fibrillation should be a patient– specific, data–driven decision. Am J Card. 1998:82:8A:72N–81N.

569. Rienstra M., Damman K., Mulder B.A. et al. Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. JACC: Heart Fail. 2013; 1:21–8.

570. Reithmann C., Dorwarth U., Dugas M. et al. Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug–induced atrial flutter. Eur Heart J. 2003;24:1264–72.

571. Ricardo S., Patricia N., Joshua A. et al. Prevalence and Prognostic Significance of Exercise–Induced Right Bundle Branch Block. Am J Cardiol. 2010;105[5]:677–80.

572. Rienstra M., van Veldhuisen D.J., Crijns H.J.G.M. et al. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. Eur Heart J. 2007;28:741–51.

573. Risgaard B., Elming H., Jensen G.V. et al. Waiting for a pacemaker: is it dangerous?

Europace. 2012;14(7):975–80.

574. Rolf S., Bruns H.J., Wichter T. et al. The ajmaline challenge in Brugada syndrome:

Diagnostic impact, safety, and recommended protocol. Eur Heart J. 2003;24:1104–12.

575. Rosenberg M.A., Samuel M., Thosani A., Zimetbaum P.J. Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study. Pacing Clin Electrophysiol. 2013;36(3):328–33.

576. Ross D.L., Johnson D.C., Denniss A.R. et al. Curative surgery for atrioventricular junctional ("AV nodal") reentrant tachycardia. J Am Coll Cardiol. 1985;6(6):1383–92.

577. Rowlands D.J. Left and right bundle branch block, left anterior and left posterior hemiblock. Eur Heart J. 1984;5 Suppl A:99–105.

578. Roy D., Talajic M., Dorian P. et al. Amiodarone to Prevent Recurrence of Atrial Fibrillation. N Engl J Med. 2000;342:913–20.

579. Ruiz Ortiz M., Romo E., Mesa D. et al. Outcomes and Safety of Antithrombotic Treatment in Patients Aged 80 Years or Older With Nonvalvular Atrial Fibrillation. Am J Cardiol. 2011;107[10]:1489–93.

580. Ruwald M., Hansen M., Lamberts M. et al. Prognosis Among Healthy Individuals Discharged With a Primary Diagnosis of Syncope. J Am Coll Cardiol. 2013;61(3):325– 581. Ruwald M.H., Abu-Zeitone A., Jons C. et al. Impact of Carvedilol and Metoprolol on Inappropriate Implantable Cardioverter-Defibrillator Therapy: The MADIT-CRT Trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). J Am Coll Cardiol.2013;62(15):1343–50.

582. Ruwald M.H., Num A.-K., Lamberts M. et al. Incidence and Influence of Hospitalization for Recurrent Syncope and Its Effect on Short- and Long-Term All-Cause and Cardiovascular Mortality. The American journal of cardiology. 2014;113:1744–50.

583. Saad E.B., d'Avila A., Costa I.P. et al. Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS score 3: a long-term outcome study. Circ Arrhythm Electrophysiol. 2011;4(5):615– 584. Sacco R.L., Boden–Albala B., Gan R. et al. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study.

Am J Epidemiol. 1998;147(3):259–68.

585. Saczynski J.S., McManus D., Zhou Z. et al. Trends in Atrial Fibrillation Complicating Acute Myocardial Infarction. Am J Cardiol. 2009;104[2]:169–74.

586. Sadanandan S., Sherrid M.V. Clinical and echocardiographic characteristics of left atrial spontaneous echo contrast in sinus rhythm. J Am Coll Cardiol. 2000;35:1932–8.

587. Sardar P., Nairooz R., Chatterjee S., et al. Meta-Analysis of Risk of Stroke or Transient Ischemic Attack With Dabigatran for Atrial Fibrillation Ablation. The American journal of cardiology. 2014;113(7):1173–7.

588. Sajadieh A., Nielsen O.W., Rasmussen V. et al. Ventricular arrhythmias and risk of death and acute myocardial infarction in apparently healthy subjects of age 55 years.

Am J Cardiol. 2006;97(9):1351–7.

589. Saliba W, Rennert G. CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation. The American journal of medicine. 2014;127(1):45-52.

590. Saliba W., Juratli N., Chung M.K. et al. Higher energy synchronized external direct current cardioversion for refractory atrial fibrillation. J Am Coll Cardiol. 1999;34:2031– 591. Sami M., Kraemer H., Harrison D.C., et al. A new method for evaluating antiarrhythmic drug efficacy. Circulation. 1980;62(6):1172–9.

592. Sanfillipo A.J., Abaskal V.M., Sheehan M. et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation. 1990;82:792– 593. Santangeli P., Di Biase L., Russo A.D. et al. Meta-analysis: Age and Effectiveness of Prophylactic Implantable Cardioverter-Defibrillators. Ann Intern Med.

2010;153(9):592–9.

594. Santangeli P., Di Biase L., Mohanty P. et al. Catheter ablation of atrial fibrillation in octogenarians: Safety and outcomes. J Cardiovasc Electrophysiol. 2012;23:687–93.

595. Santini M., Pandozi C., Colivicchi F. et al. Transoesophageal low-energy cardioversion of atrial fibrillation. Results with the oesophageal-right atrial lead configuration. Eur Heart J. 2000;21(10):848–55.

596. Sgarbossa E.B., Pinski S.L., Jaeger F.J. et al. Incidence and predictors of syncope in paced patients with sick sinus syndrome. Pacing Clin Electrophysiol. 1992;15(11 Pt 2):2055–60.

597. Sasson C., Rogers M.A.M., Dahl J. et al. Predictors of Survival From Out-of-Hospital Cardiac Arrest. Circ Cardiovasc Qual Outcomes. 2010;3(1):63–81.

598. Sairaku A., Nakano Y., Oda N. et al. Prediction of sinus node dysfunction in patients with persistent atrial flutter using the flutter cycle length. Europace. 2012;14(3):380–7.

599. Sauer A.J., Moss A.J., McNitt S. et al. Long QT syndrome in adults. J Am Coll Cardiol. 2007;49:329–37.

600. Sawit S.T., Garcia-Alvarez A., Suri B. et al. Usefulness of Cardiac Computed Tomographic Delayed Contrast Enhancement of the Left Atrial Appendage Before Pulmonary Vein Ablation. The American journal of cardiology. 2012;109[5]:677–84.

601. Scardi S., Humar F., Pandullo C., Poletti A. Oral clonidine for heart rate control in chronic atrial fibrillation. Lancet. 1993;341:1211–2.

602. Schatzkin A., Cupples L.A., Heeren T. et al. Sudden death in the Framingham Heart Study. Differences in incidence and risk factors by sex and coronary disease status.

Am J Epidemiol. 1984;120(6):888–99.

603. Schmidt H., von der Recke G., Illien S. et al. Prevalence of left atrial chamber and appendage thrombi in patients with atrial flutter and its clinical significance. J Am Coll Cardiol. 2001;38(3):778–84.

604. Schmitt J., Duray G., Gersh B.J. et al. Atrial fibrillation in acute myocardial infarction:

a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30(9):1038–45.

605. Schneider M.P., Hua T.A., Bohm M. et al. Prevention of Atrial Fibrillation by ReninAngiotensin System Inhibition: A Meta-Analysis. J Am Coll Cardiol. 2010;55(21):2299– 606. Schumacher B., Jung W., Lewalter T. et al. Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. Am J Card.

1999;83:710–3.

607. Schoonderwoerd B.A., Smit M.D., Pen L. et al. New risk factors for atrial fibrillation:

causes of “not-so-lone atrial fibrillation”. Europace. 2008;10(6):668–73.

608. Schwartz G.G., Chaitman B.R., Goldberger J.J. et al. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack. Am Heart J.

2011;161[5]:993–9.

609. Scirica B.M., Braunwald E., Belardinelli L. et al. Relationship Between Nonsustained Ventricular Tachycardia After Non-ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death. Circulation. 2010;122(5):455–62.

610. Shariff N., Desai R.V., Patel K. et al. Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation. The American Journal of Medicine. 2013;126[10]:887–93.

611. Seidl K., Hauer B., Schwick N.G. et al. Risk of thromboembolic events in patients with atrial flutter. Am J Card. 1998;82:580–3.

612. Seidl K., Hauer B., Schwick N.G. et al. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. Am J Card. 1998;82:744–8.

613. Seidl K., Rameken M., Drogemuller A. et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct–current cardioversion: Final results of the Ludwigshafen Observational Cardioversion Study. J Am Coll Cardiol. 2002;39:1436–42.

614. Sellers M.B., Newby L.K. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011;161[2]:241–6.

615. Serra-Grima R., Doate M., lvarez-Garca J. et al. Benign Prognosis of Early Repolarization Pattern in Elite Athletes After a Long Follow-Up. The American Journal of Medicine. 2014.

616. Shih–Ann Chen, Ming–Hsiung Hsieh, Ching–Tai Tai et al. Initiation of Atrial Fibrillation by Ectopic Beats Originating From the Pulmonary Veins. Circulation.

1999;100:1879–86.

617. Shah R.U., Freeman J.V., Shilane D. et al. Procedural Complications, Rehospitalizations, and Repeat Procedures After Catheter Ablation for Atrial Fibrillation. J Am Coll Cardiol. 2012;59(2):143–9.

618. Shirolkar S.C., Fiuzat M., Becker R.C. Dronedarone and vitamin K antagonists: a review of drug–drug interactions. Am Heart J. 2010;160(4):577–82.

619. Shlipak M.G., Lyons W.L., Go A.S. et al. Should the Electrocardiogram Be Used to Guide Therapy for Patients With Left Bundle-Branch Block and Suspected Myocardial Infarction? JAMA. 1999;281:714–9.

620. Shlipak M.G., Go A.S., Frederick P.D. et al. Treatment and outcomes of left bundlebranch block patients with myocardial infarction who present without chest pain. J Am Coll Cardiol. 2000;36:706–12.

621. Shotan A., Ostrzega E., Mehra A. et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol. 1997;79(8):1061–4.

622. Sim I., McDonald K.M., Lavori P.W. et al. Quantative overview of zandomized trials of amiodarone to prevent sudden cardiac death. Circulation. 1997;96:2823–9.

623. Singh B.N., Connolly S.J., Crijns H.J.G.M. et al. Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. N Engl J Med. 2007;357:987–99.

624. Sipahi I., Carrigan T.P., Rowland D.Y. et al. Impact of QRS Duration on Clinical Event Reduction With Cardiac Resynchronization Therapy: Meta-analysis of Randomized Controlled Trials. Arch Intern Med. 2011;171(16):1454–62.

625. Sjoblom J., Ljung L., Frick M. et al. Primary prevention of defibrillator implantation after myocardial infarction: clinical practice and compliance to guidelines. Europace.

2012;14(4):490–5.

626. Siu C.W., Pong V., Zhang X. et al. Risk of ischemic stroke after new–onset atrial fibrillation in patients with hyperthyroidism. Heart Rhythm. 2009;6(2):169–73.

627. Sjlander S., Sjlander A., Svensson P.J., Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace. 2014;16:631–8.

628. Skanes A.C., Krahn A.D., Yee R. et al. Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. J Am Coll Cardiol. 2001;38:167–72.

629. Slavik R.S., Tisdale J.E., Borzak S. Pharmacologic conversion of atrial fibrillation: A systematic review of available evidence. Prog Cardiovasc Dis. 2001;44:121–52.

630. Smith G.D., Dyson K., Taylor D. et al. Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD009502.

631. Sobocinski P.D., Rooth E.A., Kull V.F. et al. Improved screening for silent atrial fibrillation after ischaemic stroke. Europace. 2012;14(8):1112–6.

632. Sorajja D., Nesbitt G.C., Hodge D.O. et al. Syncope While Driving: Clinical Characteristics, Causes, and Prognosis. Circulation. 2009;120(11):928–34.

633. Soteriades E.S., Evans J.C., Larson M.G. et al. Incidence and Prognosis of Syncope.

N Engl J Med. 2002;347:878–85.

634. Southworth M.R., Zarembski D., Viana M.,et al. Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation.

Am J Card. 1999;83:1629–32.

635. Stec S.M., Grabczak E.M., Bielicki P. et al. Diagnosis and Management of Premature Ventricular Complexes–Associated Chronic Cough. Chest. 2009;135(6):1535–41.

636. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator Implantation Early after Myocardial Infarction. N Engl J Med. 2009;361(15):1427–36.

637. Steinberg J.S., Romanov A., Musat D. et al. Prophylactic pulmonary vein isolation during isthmus ablation for atrial flutter: The PREVENT AF Study I. Heart Rhythm 2014.

638. Stellbrink C et al. Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin and Oral Anticoagulants for Prevention of Thromboembolic Complications in Cardioversion of Nonvalvular Atrial Fibrillation. Circulation. 2004;109:997–1003.

639. Stenestrand U., Lindback J., Wallentin L. et al. Anticoagulation Therapy in Atrial Fibrillation in Combination With Acute Myocardial Infarction Influences Long-term Outcome: A Prospective Cohort Study From the RIKS-HIA. Circulation. 2005;112:3225– 640. Stergiou G.S., Kollias A., Destounis A., Tzamouranis D. Automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis. J Hypertens.

2012;30(11):2074–82.

641. Strickberger S.A.,Man K.C.,Daoud E.G. et al. Adenosine-Induced Atrial Arrhythmia:

A Prospective Analysis. Ann Intern Med. 1997;127:417–22.

642. Strickberger S.A., Ip J., Saksena S. et al. Relationship between atrial tachyarrhythmias and symptoms. Heart Rhythm. 2005;2(2):125–31.

643. Strote J.A., Maynard C., Olsufka M. et al. Comparison of Role of Early to Later or No Cardiac Catheterization After Resuscitation From Out-of-Hospital Cardiac Arrest. Am J Cardiol. 2012;109[4]:451–4.

644. Sullivan J.M., Ramanathan K.B. Management of medical problems in pregnancy — severe heart disease. N Engl J Med. 1985;313:304–9.

645. Supple G.E., Ren J.F., Zado E.S. et al. Mobile Thrombus on Device Leads in Patients Undergoing Ablation. Circulation. 2011;124(7):772–8.

646. Surawicz B. Transient T wave abnormalities after cessation of ventricular preexcitation: memory of what? J Cardiovasc Electrophysiol. 1996;7(1):51–9.

647. Suri R.M., Vanoverschelde J., Grigioni F., et al. Association Between Early Surgical Intervention vs Watchful Waiting and Outcomes for Mitral Regurgitation Due to Flail Mitral Valve Leaflets. JAMA. 2013;310(6):609–16.

648. Sutton R., Kenny R.A. The natural history of sick sinus syndrome. Pacing Clin Electrophysiol. 1986;9:1110–4.

649. Swindle J.P., Rich M.W., McCann P. et al. Implantable Cardiac Device Procedures in Older Patients: Use and In-Hospital Outcomes. Arch Intern Med. 2010;170(7):631– 650. Swiryn S. RATE registry: Longer bouts of atrial arrhythmia have worse outcomes.

American Heart Association 2012 Scientific Sessions. http://www.theheart.org/article/1475603.do.

651. Sy R.W., van der Werf C., Chattha I.S. et al. Derivation and Validation of a Simple Exercise-Based Algorithm for Prediction of Genetic Testing in Relatives of LQTS Probands. Circulation. 2011;124(20):2187–94.

652. Schwartz P.J., Moss A.J., Vincent G.M., Crampton R.S. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993;88:782–4.

653. Taggart N.W., Haglund C.M., Tester D.J. et al. Diagnostic miscues in congenital long–QT syndrome. Circulation. 2007;115:2613–20.

654. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J. 2001;22:1374–450.

655. Teo K.K., Yusuf S., Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials.

JAMA. 1993;270:1589–95.

656. Terasawa T., Balk E.M., Chung M. et al. Systematic Review: Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation. Ann Intern Med.

2009;151(3):191–202.

657. Tischer T.S., Hollstein A., Voss W. et al. A historical perspective of pacemaker infections: 40-years single-centre experience. Europace. 2014;16(2):235-40.

658. Toff W.D., Camm A.J., Skehan J.D., the United Kingdom Pacing and Cardiovascular Events (UKPACE) Trial Investigators. Single–Chamber versus Dual-Chamber Pacing for High–Grade Atrioventricular Block. N Engl J Med. 2005;353(2):145–55.

659. Trivalle C., Doucet J., Chassagne P. et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc. 1996;44 (1):50–3.

660. Tsadok M.A., Jackevicius C.A., Essebag V. et al. Rhythm Versus Rate Control Therapy and Subsequent Stroke or Transient Ischemic Attack in Patients With Atrial Fibrillation. Circulation. 2012;126(23):2680–7.

661. Tzivoni D., Keren A. Supression of ventricular arrhythmias by magnesium. Am J Card. 1990;65:1397–9.

662. Update of guidelines on sudden cardiac death of European Society of Cardiology.

Eur Heart J. 2003;24:13–5.

663. Ulimoen S.R., Enger S., Carlson J. et al. Comparison of Four Single-Drug Regimens on Ventricular Rate and Arrhythmia-Related Symptoms in Patients With Permanent Atrial Fibrillation. The American journal of cardiology. 2013;111[2]:225–30.

664. Upadhyay G.A., Choudhry N.K., Auricchio A. et al. Cardiac Resynchronization in Patients With Atrial Fibrillation: A Meta-Analysis of Prospective Cohort Studies. J Am Coll Cardiol. 2008;52:1239–46.

665. Van Brabandt H., Neyt M., Devos C. Effectiveness of catheter ablation of atrial fibrillation in Belgian practice: a cohort analysis on administrative data. Europace.

2013;15 (5):663–8.

666. Van Gelder I.C., Crijns H.J., Tieleman R.G. et al. Chronic atrial fibrillation: success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med.

1996;156:2585–92.

667. Van Gelder I.C., Groenveld H.F., Crijns H.J.G.M. et al. Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. N Engl J Med. 2010;362(15):1363–73.

668. Van Gelder I.C., Haegeli L.M., Brandes A. et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace. 2011;13(11):1517–25.

669. Van Noord T., Van Gelder I.C., Crijns H.J. How to enhance acute outcome of electrical cardioversion by drug therapy: importance of immediate reinitiation of atrial fibrillation. J Cardiovasc Electrophysiol. 2002;13(8):822–5.

670. Van Rees J.B., de Bie M.K., Thijssen J. et al. Implantation-Related Complications of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Devices: A Systematic Review of Randomized Clinical Trials. J Am Coll Cardiol.

2011;58(10):995–1000.

671. Van Rees J.B., Willem Borleffs C.J., Thijssen J. et al. Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, survival gain.

Europace. 2012;14(1):66–73.

672. Vazquez S.R., Johnson S.A., Rondina M.T. Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. Thromb Res. 2010;126(2):e69–77.

673. Vega F., Mehta M., Young M.-L. Successful Radiofrequency Catheter Ablation of a Chaotic Atrial Tachycardia. HeartWeb. 1999;4(9).

674. Verma A., Champagne J., Sapp J. et al. Discerning the Incidence of Symptomatic and Asymptomatic Episodes of Atrial Fibrillation Before and After Catheter Ablation (DISCERN AF): A Prospective, Multicenter Study. JAMA Intern Med. 2013;173(2):149– 675. Vidal E., Tom H., Robert W.P. et al. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J Am Coll Cardiol. 2003;41:249–54.

676. Viles-Gonzalez J.F., Kar S., Douglas P. et al. The Clinical Impact of Incomplete Left Atrial Appendage Closure With the Watchman Device in Patients With Atrial Fibrillation:

A PROTECT AF Substudy. J Am Coll Cardiol. 2012;59(10):923–9.

677. Viskin S. The QT interval: too long, too short or just right. Heart Rhythm.

2009;6(5):711–5.

678. Volgman A.S., Carberry P.A., Stambler B. et al. Conversion Efficacy and Safety of Intravenous Ibutilide Compared With Intravenous Procainamide in Patients With Atrial Flutter or Fibrillation. J Am Coll Cardiol. 1998;31:1414–9.

679. Volpi A., Cavalli A., Turato R. et al. Incidence and short–term prognosis of late sustained ventricular tachycardia after myocardial infarction: results of the GISSI-3 Data Base. Am Heart J. 2001;142:87–92.

680. Vrtovec B., Knezevic I., Poglajen G. et al. Relation of B-Type Natriuretic Peptide Level in Heart Failure to Sudden Cardiac Death in Patients With and Without QT Interval Prolongation. The American journal of cardiology. 2013;111[6]:886-90.

681. Waldo A.L., Prystowsky E.N. Drug Treatment of Atrial Fibrillation in the Managed Care Era. Am J Card. 1998;81:23C–9C.

682. Wallentin L., Yusuf S., Ezekowitz M.D. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation. The Lancet. 2010;376:975–83.

683. Wang Y.L., Liu X.U., Tan H.W. et al. Evaluation of Linear Lesions in the Left and Right Atrium in Ablation of Long-standing Atrial Fibrillation. Pacing and Clinical Electrophysiology. 2013;36(10):1202–10.

684. Wazni O.M., Marrouche N.F., Martin D.O. et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005;293:2634–40.

685. Weber B.E., Kapoor W.N. Evaluation and outcomes of patients with palpitations. Am J Med. 1996;100:138–48.

686. Weerasooriya R., Davis M., Powell A. et al. The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol. 2003;41:1697– 687. Wellens H.J.J., Brugada P., Heddle W.F. The value of the 12-lead ECG in diagnosing and mechanism of a tachycardia: a servey among 22 cardiologists. J Am Coll Cardiol.

1984;4:176–9.

688. Wellens H.J., Chu-Pak Lau, Luderitz B. et al. Atrioverter: An Implantable Device for the Treatment of Atrial Fibrillation. Circulation. 1998;98:1651–6.

689. Wellens H.J. Pulmonary vein ablation in atrial fibrillation: hype or hope? Circulation.

2000;102:2562–4.

690. Welles C.C., Whooley M.A., Na B. et al. The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: Data from the Heart and Soul Study. Am Heart J. 2011;162[3]:555–61.

691. Weerasooriya R., Khairy P., Litalien J. et al. Catheter Ablation for Atrial Fibrillation:

Are Results Maintained at 5 Years of Follow-up? J Am Coll Cardiol. 2011;57(2):160– 692. Whitbeck M.G., Charnigo R.J., Khairy P. et al. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J 2013;34(20):1481–8.

693. Widerhorn J., Widerhorn A.L.M., Rahimtoola S.H., Elkayam U. WPW syndrome during pregnancy: Increased incidence of supraventricular arrhythmias. Am Heart J.

1992;124:796.

694. Wiesel J., Fitzig L., Herschman Y., Messineo F.C. Detection of atrial fibrillation using a modified microlife blood pressure monitor. Am J Hypertens. 2009;22(8):848–52.